The BVS is made of polylactide, a naturally dissolvable material that is commonly used in medical implants such as dissolving sutures
It works by restoring blood flow to the heart similar to a metallic stent, but then dissolves into the body over time, leaving behind a treated vessel that may resume more natural function and movement because it is free of a permanent metallic stent.
Abbott’s BVS is made of polylactide, a naturally dissolvable material that is commonly used in medical implants such as dissolving sutures.
The potential long-term benefits of a scaffold that dissolves are significant. The vessel may expand and contract as needed to increase the flow of blood to the heart in response to normal activities such as exercising; treatment and diagnostic options are broadened; the need for long-term treatment with anti-clotting medications may be reduced; and future interventions would be unobstructed as it would be by a permanent implant.
“With the launch of BVS we can offer our patients a significant advancement in the treatment of coronary artery disease. The structure starts to resorb within one year, allowing the vessel the potential to flex, pulsate and dilate in response to normal activities such as exercise,” said Dr. Ashok Seth, Chairman, Cardiac Sciences, Fortis Healthcare. “This revolutionary technology may allow blood vessels to return to a more natural state and expand long-term diagnostic and treatment options.”
The launch of Abbott’s BVS is supported by a clinical trial program that encompasses five studies in more than 20 countries around the world, including India. BVS has been studied in Indian population and has shown robust clinical results . Study data indicate that Abbotts BVS perform similar to a best-in-class drug eluting stent across traditional measures such as major adverse cardiovascular events (MACE) and target lesion revascularization (TLR), while providing patients with the added benefits associated with a device that dissolves over time.
As the scaffold dissolves, vascular function is potentially restored to the blood vessel, allowing more blood to flow through the vessel as the body requires. BVS has been implanted in more than 3,000 patients in over 30 countries worldwide in clinical trials and commercial settings.
“BVS is a leading example of Abbott’s commitment to innovation “ from the initial device developed nearly 10 years ago to the expansion of our manufacturing capabilities to support this launch,” said Amit Kumar, regional director and general manager, South Asia and Southeast Asia .